Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. QP-6211 demonstrated ...

CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive ...

Ultragenyx Pharmaceutical (NASDAQ: RARE) and Mereo BioPharma Group (NASDAQ: MREO) may be wishing for a happy new year in 2026 after the companies ended 2025 by announcing bad news—namely, the failures ...

This study was funded by grants from the Natural Environment Research Council (NE/S011188/1) and the European Research Council (SELECTHAPLOID - 101001341) The Arctic Ocean current is at its warmest in ...

SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage ...

After decades of intense focus on genetics, the biomedical research community is undergoing a major shift, focusing on a new framework called "exposomics." Similar to the way scientists work to map ...

Chief Research Scientist, CSIRO Environment; Executive Director, Global Carbon Project, CSIRO Pep Canadell receives funding from the Australian National Environmental Science Program - Climate Systems ...

FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and ...

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study ...

A massive conservation project to track one of the most elusive predators on Earth, which resides in Jammu and Kashmir, has yielded encouraging and remarkable results. As Research Matters reports, a ...